Skinny Labels, Big Savings Act
- Bill Number
- H.R. 6485
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Commerce
- Status
- Introduced
- Latest Action
- 2025-12-05: Referred to the House Committee on the Judiciary.
- Last Updated
- 2026-06-24T08:08:21Z
AI-Generated Summary
Purpose of the Legislation
The "Skinny Labels, Big Savings Act" (H.R. 6485) aims to protect generic drug and biosimilar manufacturers from patent infringement lawsuits when they develop and market "skinny label" versions of drugs or biological products. These skinny labels exclude patented methods of use (specific ways the drug can be prescribed), allowing competition to lower drug prices while respecting patent rights for other uses.
Key Provisions
- Safe Harbor for Generic Drugs: Under new 35 U.S.C. § 271(h), activities like submitting applications for generic drug approval (via Abbreviated New Drug Applications or ANDAs under the Federal Food, Drug, and Cosmetic Act), promoting or marketing the drug with labeling that omits patented uses, and describing it as a generic equivalent are not considered patent infringement. This applies only if the labeling, promotion, or marketing does not mention the patented condition of use.
- Safe Harbor for Biosimilars: Under new 35 U.S.C. § 271(i), similar protections apply to biosimilar biological products (close copies of brand-name biologics). This includes submitting applications under the Public Health Service Act, describing the product as biosimilar or interchangeable, and promoting or marketing it with labeling that avoids the patented use, provided it has not been approved for that use and does not reference it.
- Definitions: New 35 U.S.C. § 271(j) defines key terms like "biological product," "biosimilar," "labeling," "promoting," and "commercial marketing" by referencing existing regulations from the Food and Drug Administration (FDA) and other laws.
- Retroactive Application: The law applies to all relevant conduct (before, on, or after enactment) and any ongoing court cases or proceedings as of the enactment date.
Significant Changes to Existing Law
- Amends Section 271 of the Patent Act (35 U.S.C. § 271), which defines patent infringement, by adding explicit safe harbor protections for "method of use" patents (patents on how a drug is used to treat specific conditions).
- Builds on the Hatch-Waxman Act (which allows generics to carve out patented uses in labeling) but provides stronger, codified defenses against infringement claims for direct, induced, or contributory infringement—addressing uncertainties from recent court cases where skinny labels faced legal challenges.
- Redesignates existing subsections (h) and (i) as (k) and (l) to accommodate the new additions.
Potential Impacts
- On Citizens: Could reduce prescription drug costs by encouraging more generic drugs and biosimilars to enter the market faster, benefiting patients and healthcare consumers with affordable alternatives.
- On Government Agencies: The FDA may see streamlined approvals for generics and biosimilars with fewer patent disputes, potentially reducing administrative burdens related to patent listings and certifications.
- On International Relations: Minimal direct impact, though it may influence global pharmaceutical trade by making U.S. markets more attractive for international generic manufacturers, aligning with efforts to promote drug affordability worldwide.
- Broader Economy: Likely to increase competition in the pharmaceutical sector, potentially saving billions in healthcare spending, but could affect revenue for brand-name drug companies.
Main Stakeholders Affected
- Generic Drug and Biosimilar Manufacturers: Gain legal protections to launch products without infringement risks, enabling quicker market entry.
- Brand-Name Pharmaceutical Companies: Face reduced ability to block competition via method-of-use patents, potentially limiting exclusivity periods for certain indications.
- Patients and Healthcare Payers: Benefit from lower prices and increased access to affordable medications.
- FDA and Courts: Experience clarified rules for patent challenges, possibly reducing litigation volume in drug approval processes.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Strengthens the balance between patent incentives for innovation and antitrust-like promotion of competition under patent law; may reduce "evergreening" tactics (extending patents via minor method claims) and clarify "skinny label" defenses in infringement lawsuits, potentially leading to fewer appeals in federal courts.
- Constitutional Implications: None apparent; aligns with the Constitution's patent clause (promoting science and useful arts) by protecting public access to medicines without unduly restricting inventors' rights.
- Political Implications: Represents a bipartisan effort (introduced by representatives from both parties) to address high drug prices, a key public concern, and could influence future pharma policy debates by favoring access over prolonged exclusivity.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (6)
Rep. Lofgren, Zoe [D-CA-18], Rep. Kiggans, Jennifer A. [R-VA-2], Rep. Suozzi, Thomas R. [D-NY-3], Rep. Pfluger, August [R-TX-11], Rep. Grothman, Glenn [R-WI-6], Rep. Craig, Angie [D-MN-2]
Recent Actions
- 2025-12-05: Referred to the House Committee on the Judiciary.
- 2025-12-05: Introduced in House
- 2025-12-05: Introduced in House
Bill Versions
- Skinny Labels, Big Savings Act — issued 2025-12-05 — PDF (5 pages)